• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

    4/30/24 8:06:42 AM ET
    $ADXN
    $ATNF
    $BRTX
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADXN alert in real time by email

    Gainers

    • Cyclacel Pharmaceuticals (NASDAQ:CYCC) stock moved upwards by 50.0% to $2.04 during Tuesday's pre-market session. The company's market cap stands at $2.6 million.
    • GeneDx Hldgs (NASDAQ:WGS) shares rose 43.54% to $15.79. The company's market cap stands at $411.3 million. As per the news, the Q1 earnings report came out yesterday.
    • BioRestorative Therapies (NASDAQ:BRTX) shares moved upwards by 16.93% to $1.45. The company's market cap stands at $9.8 million.
    • Vaccinex (NASDAQ:VCNX) shares moved upwards by 15.72% to $6.77. The company's market cap stands at $10.7 million.
    • Addex Therapeutics (NASDAQ:ADXN) stock moved upwards by 14.19% to $8.61. The market value of their outstanding shares is at $9.2 million.
    • Tenet Healthcare (NYSE:THC) stock increased by 9.93% to $109.0. The company's market cap stands at $10.8 billion. The company's, Q1 earnings came out today.

    Losers

    • SHL Telemedicine (NASDAQ:SHLT) stock decreased by 10.0% to $5.0 during Tuesday's pre-market session. The company's market cap stands at $81.9 million.
    • Nektar Therapeutics (NASDAQ:NKTR) stock declined by 8.87% to $1.33. The market value of their outstanding shares is at $244.3 million.
    • GlucoTrack (NASDAQ:GCTK) shares fell 8.17% to $0.51. The market value of their outstanding shares is at $13.7 million.
    • GE HealthCare Techs (NASDAQ:GEHC) shares declined by 7.81% to $82.0. The market value of their outstanding shares is at $37.4 billion. As per the news, the Q1 earnings report came out today.
    • Virios Therapeutics (NASDAQ:VIRI) stock fell 7.28% to $0.44. The market value of their outstanding shares is at $8.3 million.
    • 180 Life Sciences (NASDAQ:ATNF) shares decreased by 7.15% to $1.82. The market value of their outstanding shares is at $1.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADXN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADXN
    $ATNF
    $BRTX
    $CYCC

    CompanyDatePrice TargetRatingAnalyst
    Nektar Therapeutics
    $NKTR
    2/10/2026Mkt Perform → Outperform
    William Blair
    GeneDx Holdings Corp.
    $WGS
    2/9/2026$155.00Equal Weight → Overweight
    Wells Fargo
    GE HealthCare Technologies Inc.
    $GEHC
    1/15/2026$77.00Neutral → Sell
    UBS
    Nektar Therapeutics
    $NKTR
    11/26/2025$102.00Buy
    Citigroup
    GeneDx Holdings Corp.
    $WGS
    10/20/2025$155.00Buy
    Canaccord Genuity
    Tenet Healthcare Corporation
    $THC
    10/14/2025$224.00Buy
    Goldman
    GE HealthCare Technologies Inc.
    $GEHC
    10/13/2025$86.00Equal Weight
    Barclays
    GE HealthCare Technologies Inc.
    $GEHC
    10/7/2025$83.00Buy → Neutral
    Citigroup
    More analyst ratings

    $ADXN
    $ATNF
    $BRTX
    $CYCC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Meister Keith A. bought $13,460,090 worth of shares (169,521 units at $79.40) (SEC Form 4)

    4 - GeneDx Holdings Corp. (0001818331) (Issuer)

    3/5/26 7:19:34 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Director Meister Keith A. bought $3,007,997 worth of shares (50,000 units at $60.16) (SEC Form 4)

    4 - GeneDx Holdings Corp. (0001818331) (Issuer)

    5/16/25 4:00:06 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Director Meister Keith A. bought $5,600,994 worth of shares (100,000 units at $56.01) (SEC Form 4)

    4 - GeneDx Holdings Corp. (0001818331) (Issuer)

    5/12/25 7:46:55 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    $ADXN
    $ATNF
    $BRTX
    $CYCC
    SEC Filings

    View All

    SEC Form 144 filed by Tenet Healthcare Corporation

    144 - TENET HEALTHCARE CORP (0000070318) (Subject)

    3/9/26 1:08:26 PM ET
    $THC
    Hospital/Nursing Management
    Health Care

    SEC Form SCHEDULE 13G filed by Nektar Therapeutics

    SCHEDULE 13G - NEKTAR THERAPEUTICS (0000906709) (Subject)

    3/6/26 10:05:20 AM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GeneDx Holdings Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation

    8-K - GeneDx Holdings Corp. (0001818331) (Filer)

    3/2/26 7:02:39 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    $ADXN
    $ATNF
    $BRTX
    $CYCC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Nektar Therapeutics upgraded by William Blair

    William Blair upgraded Nektar Therapeutics from Mkt Perform to Outperform

    2/10/26 11:48:14 AM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GeneDx upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded GeneDx from Equal Weight to Overweight and set a new price target of $155.00

    2/9/26 6:58:22 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    GE HealthCare downgraded by UBS with a new price target

    UBS downgraded GE HealthCare from Neutral to Sell and set a new price target of $77.00

    1/15/26 8:32:16 AM ET
    $GEHC
    Medical Electronics
    Health Care

    $ADXN
    $ATNF
    $BRTX
    $CYCC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

    Program to expand access to exome sequencing to help clinicians confirm diagnosis and guide clinical decision-making in NPC GeneDx (NASDAQ:WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced a new genetic testing program with Zevra Therapeutics, Inc. (NASDAQ:ZVRA), a commercial-stage biopharmaceutical company focused on bringing life-changing therapeutics to people living with rare diseases. The Niemann-Pick Disease type C (NPC) Sponsored Genetic Testing Program is designed to expand access to GeneDx's industry-leading ExomeDx™ test for patients with suspected Niemann-Pick disease type C, helping clinicians reach accurate diag

    3/10/26 8:30:00 AM ET
    $WGS
    $ZVRA
    Retail: Computer Software & Peripheral Equipment
    Technology
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Glucotrack to Present at LSI USA '26 Medtech Innovation Summit

    RUTHERFORD, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc.("Glucotrack", or the "Company") (NASDAQ:GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that Paul V. Goode, PhD, President and Chief Executive Officer, will present at LSI USA '26 Summit, taking place March 16-20, 2026, in Dana Point, California. The presentation will take place on Tuesday, March 17 at 8:15 a.m. PT. Dr. Goode will introduce Glucotrack's continuous blood glucose monitor (CBGM) technology, share its positive first-in-human study results, outline the Company's regulatory strategy and commercialization

    3/10/26 8:01:00 AM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    GE HealthCare announces U.S. FDA 510(k) clearance for View, a next‑generation diagnostic viewer enabling anywhere‑access to radiologists

    Built for the demands of modern imaging, View streamlines workflows, and helps enhance patient care as the advanced diagnostic viewer powering the Genesis Radiology Workspace GE HealthCare today announced that View, the powerful viewer within the Genesis™ Radiology Workspace, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). Designed as a fast, diagnostic, zero‑footprint viewer, View serves as the core anchor of the Genesis Radiology Workspace.2 This next‑generation solution aims to transform radiology workflows, unify the user experience, and empower radiologists with greater efficiency and precision. Studies show that radiologists spend up to 44% of the

    3/9/26 9:00:00 AM ET
    $GEHC
    Medical Electronics
    Health Care

    $ADXN
    $ATNF
    $BRTX
    $CYCC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Maloney Michael T. claimed ownership of 101,990 shares (SEC Form 3)

    3 - TENET HEALTHCARE CORP (0000070318) (Issuer)

    3/9/26 8:00:04 PM ET
    $THC
    Hospital/Nursing Management
    Health Care

    CHIEF FINANCIAL OFFICER Feeley Kevin was granted 1,986 shares, increasing direct ownership by 11% to 20,660 units (SEC Form 4)

    4 - GeneDx Holdings Corp. (0001818331) (Issuer)

    3/9/26 7:56:01 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    CHIEF EXECUTIVE OFFICER Stueland Katherine was granted 3,404 shares, increasing direct ownership by 9% to 42,087 units (SEC Form 4)

    4 - GeneDx Holdings Corp. (0001818331) (Issuer)

    3/9/26 7:54:54 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    $ADXN
    $ATNF
    $BRTX
    $CYCC
    Financials

    Live finance-specific insights

    View All

    Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets

    SAN FRANCISCO, Feb. 26, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2025 on Thursday, March 12, 2026, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar web

    2/26/26 6:00:00 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GeneDx Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms Guidance for Full Year 2026

    Reported fourth quarter 2025 revenues of $121.0 million with 32% year-over-year growth in exome and genome test revenue (42% excluding a one-time 2024 benefit) Accelerated exome and genome volume growth to 34% year-over-year Reported fourth quarter 2025 adjusted gross margin1 of 71% Reported fourth quarter 2025 adjusted net income1 of $4.4 million Reaffirmed full year 2026 guidance of $540 to $555 million in revenue with 33-35% exome and genome growth GeneDx to host conference call today at 8:30 a.m. ET GeneDx Holdings Corp. (NASDAQ:WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today reported its financial results for t

    2/23/26 6:30:00 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    GE HealthCare announces cash dividend for first quarter of 2026

    The Board of Directors of GE HealthCare Technologies Inc. (NASDAQ:GEHC) today declared a cash dividend of $0.035 per share of Common Stock for the first quarter of 2026 payable on May 15, 2026, to all shareholders of record as of April 3, 2026. About GE HealthCare Technologies Inc. GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world's most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Imaging, Advanced Visualization Solutions, Patie

    2/12/26 6:11:00 PM ET
    $GEHC
    Medical Electronics
    Health Care

    $ADXN
    $ATNF
    $BRTX
    $CYCC
    Leadership Updates

    Live Leadership Updates

    View All

    GeneDx Appoints Dr. Linda Genen as Chief Medical Officer to Accelerate the Future of Genomic-First Care

    Recognized neonatologist and payer-strategy leader joins GeneDx to expand earlier diagnosis and establish genomics as a standard of care across healthcare GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights today announced Linda Genen, MD, MPH as Chief Medical Officer to further strengthen the company's commitment to delivering earlier answers and better outcomes for families through genomic insights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106493899/en/GeneDx Names Dr. Linda Genen, MD, MPH as Chief Medical Officer In her role at GeneDx, Dr. Genen will oversee Medical and Cli

    1/6/26 8:30:00 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Ryder System, Inc. Elects Tammy Romo to Its Board of Directors

    The board of directors of Ryder System, Inc. (NYSE:R) today announces the appointment of Tammy Romo, 63, to its board, effective January 5, 2026. Romo will serve as a member of the Audit and Finance Committees. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219927656/en/Ryder appoints Tammy Romo to its board of directors, effective January 5, 2026. "The board nominated Tammy as a director for her impressive results-oriented leadership style, proven ability to provide strategic oversight in complex public company settings, and her deep transportation expertise," says Ryder Chairman and CEO Robert Sanchez. "Tammy's experience in

    12/19/25 6:55:00 AM ET
    $R
    $THC
    Rental/Leasing Companies
    Consumer Discretionary
    Hospital/Nursing Management
    Health Care

    Glucotrack Reports Third Quarter 2025 Financial Results and Provides Update on Recent Corporate Highlights

    Company to submit Investigational Device Exemption (IDE) to FDA for novel CBGM technology in Spring 2026 Expanded clinical advisory team with appointment of pain management and medical technology expert, Usman Latif, MD, MBA Strengthened balance sheet, cash and cash equivalents expected to fund operations through March 2026, including long-term feasibility clinical trials and achievement of related milestones Rutherford, NJ, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today reported financial results

    11/13/25 4:05:00 PM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    $ADXN
    $ATNF
    $BRTX
    $CYCC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by GeneDx Holdings Corp.

    SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)

    11/20/24 9:36:13 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Amendment: SEC Form SC 13D/A filed by GeneDx Holdings Corp.

    SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)

    11/19/24 8:00:24 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Amendment: SEC Form SC 13D/A filed by Vaccinex Inc.

    SC 13D/A - VACCINEX, INC. (0001205922) (Subject)

    11/18/24 4:15:28 PM ET
    $VCNX
    Biotechnology: Pharmaceutical Preparations
    Health Care